2018 Press Releases

Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
May 17, 2018BeyondSpring to Present Positive Data From Prospective Phase 2 Trial Comparing Plinabulin to Neulasta for the Prevention of Chemotherapy-Induced Neutropenia at 2018 ASCO Annual MeetingPrinter Friendly Version
May 7, 2018BeyondSpring to Present at the Deutsche Bank 43rd Annual Health Care ConferencePrinter Friendly Version
April 25, 2018BeyondSpring to Present Neutropenia Clinical Trial Data on Lead Asset, Plinabulin, at 2018 ASCO Annual MeetingPrinter Friendly Version
April 17, 2018BeyondSpring Presents Lead Asset’s Mechanism Data for Prevention of Chemotherapy-Induced NeutropeniaPrinter Friendly Version
April 3, 2018BeyondSpring Files Its 2017 Annual Report on Form 20-FPrinter Friendly Version
April 3, 2018BeyondSpring Provides Operational Update and Fourth-Quarter and Full-Year 2017 Financial ResultsPrinter Friendly Version
March 27, 2018BeyondSpring to Host Fourth-Quarter and Full-Year 2017 Financial Results Conference Call on April 3, 2018Printer Friendly Version
March 27, 2018BeyondSpring Appoints Edward Dongheng Liu as Chief Financial OfficerPrinter Friendly Version
March 19, 2018BeyondSpring Announces Initiation of Phase 3 Clinical Development for Plinabulin for Prevention of Chemotherapy-Induced NeutropeniaPrinter Friendly Version
March 15, 2018BeyondSpring Chief Medical Officer Presents at Three Prominent Industry Conferences in March 2018Printer Friendly Version
February 7, 2018BeyondSpring to Present at Upcoming Investor ConferencesPrinter Friendly Version
February 5, 2018BeyondSpring Summarizes Key Messages from KOL Call regarding Lead Asset Plinabulin for the Prevention of Docetaxel Chemotherapy-Induced NeutropeniaPrinter Friendly Version
January 26, 2018BeyondSpring Presents Promising Data for Lead Asset Plinabulin at 2018 ASCO-SITC Clinical Immuno-Oncology SymposiumPrinter Friendly Version
January 17, 2018BeyondSpring to Present Data from Phase 2 Portion of Study 105 Phase 2/3 Trial with Plinabulin for the Prevention of Docetaxel Chemotherapy-Induced Neutropenia at 2018 ASCO-SITC Clinical Immuno-Oncology SymposiumPrinter Friendly Version
January 5, 2018BeyondSpring to Present at the 10th Annual Biotech ShowcasePrinter Friendly Version
January 3, 2018BeyondSpring Appoints Life Sciences Veteran Patrick Fabbio to Board of Directors as an Independent MemberPrinter Friendly Version
Print Page Print Page | Email Page Email Page | RSS Feeds RSS Feeds | Email Alerts Email Alerts | IR Contacts Contact IR | Financial Tear Sheet Financial Tear Sheet